These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
572 related articles for article (PubMed ID: 32521117)
1. Identification and validation of a combined hypoxia and immune index for triple-negative breast cancer. Zheng S; Zou Y; Liang JY; Xiao W; Yang A; Meng T; Lu S; Luo Z; Xie X Mol Oncol; 2020 Nov; 14(11):2814-2833. PubMed ID: 32521117 [TBL] [Abstract][Full Text] [Related]
2. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer. Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184 [TBL] [Abstract][Full Text] [Related]
3. Development and validation of a stromal immune phenotype classifier for predicting immune activity and prognosis in triple-negative breast cancer. Zheng S; Zou Y; Xie X; Liang JY; Yang A; Yu K; Wang J; Tang H; Xie X Int J Cancer; 2020 Jul; 147(2):542-553. PubMed ID: 32285442 [TBL] [Abstract][Full Text] [Related]
4. Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer. Brooks JM; Menezes AN; Ibrahim M; Archer L; Lal N; Bagnall CJ; von Zeidler SV; Valentine HR; Spruce RJ; Batis N; Bryant JL; Hartley M; Kaul B; Ryan GB; Bao R; Khattri A; Lee SP; Ogbureke KUE; Middleton G; Tennant DA; Beggs AD; Deeks J; West CML; Cazier JB; Willcox BE; Seiwert TY; Mehanna H Clin Cancer Res; 2019 Sep; 25(17):5315-5328. PubMed ID: 31182433 [TBL] [Abstract][Full Text] [Related]
5. A novel fatty-acid metabolism-based classification for triple negative breast cancer. Yang X; Tang W; He Y; An H; Wang J Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837 [TBL] [Abstract][Full Text] [Related]
6. A risk scoring system based on tumor microenvironment cells to predict prognosis and immune activity in triple-negative breast cancer. Yang A; Wu M; Ni M; Zhang L; Li M; Wei P; Yang Y; Xiao W; An X Breast Cancer; 2022 May; 29(3):468-477. PubMed ID: 35061208 [TBL] [Abstract][Full Text] [Related]
7. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer. Shen X; Zhong J; He J; Han J; Chen N Front Immunol; 2022; 13():978092. PubMed ID: 36105819 [TBL] [Abstract][Full Text] [Related]
8. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer. Zhang J; Zhang M; Tian Q; Yang J Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794 [TBL] [Abstract][Full Text] [Related]
9. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer. Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558 [TBL] [Abstract][Full Text] [Related]
10. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer. Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120 [TBL] [Abstract][Full Text] [Related]
11. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype. Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W Front Immunol; 2021; 12():749459. PubMed ID: 34603338 [TBL] [Abstract][Full Text] [Related]
12. Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study. Wang K; Li HL; Xiong YF; Shi Y; Li ZY; Li J; Zhang X; Li HY Cancer Med; 2019 Feb; 8(2):686-700. PubMed ID: 30677255 [TBL] [Abstract][Full Text] [Related]
13. Combined mRNAs and clinical factors model on predicting prognosis in patients with triple-negative breast cancer. Hu Y; Zou D PLoS One; 2021; 16(12):e0260811. PubMed ID: 34965257 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer. Lin F; Huang J; Zhu W; Jiang T; Guo J; Xia W; Chen M; Guo L; Deng W; Lin H Front Immunol; 2023; 14():1218987. PubMed ID: 37575241 [TBL] [Abstract][Full Text] [Related]
15. Integrating machine learning algorithms and multiple immunohistochemistry validation to unveil novel diagnostic markers based on costimulatory molecules for predicting immune microenvironment status in triple-negative breast cancer. Zhang C; Zhai W; Ma Y; Wu M; Cai Q; Huang J; Zhou Z; Duan F Front Immunol; 2024; 15():1424259. PubMed ID: 39007147 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of novel three-long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple-negative breast cancer. Fan CN; Ma L; Liu N J Cell Biochem; 2019 Mar; 120(3):3185-3196. PubMed ID: 30203490 [TBL] [Abstract][Full Text] [Related]
17. Predicting the Prognosis and Immunotherapeutic Response of Triple-Negative Breast Cancer by Constructing a Prognostic Model Based on CD8+ T Cell-Related Immune Genes. Li NN; Qiu XT; Xue JS; Yi LM; Chen ML; Huang ZJ Biomed Environ Sci; 2024 Jun; 37(6):581-593. PubMed ID: 38988109 [TBL] [Abstract][Full Text] [Related]
18. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer. Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X Front Immunol; 2021; 12():725223. PubMed ID: 34484235 [TBL] [Abstract][Full Text] [Related]
19. Novel molecular insights into pyroptosis in triple-negative breast cancer prognosis and immunotherapy. Yu B; Luo J; Yang Y; Zhen K; Shen B J Gene Med; 2024 Jan; 26(1):e3645. PubMed ID: 38041540 [TBL] [Abstract][Full Text] [Related]
20. A novel immune checkpoint-related gene signature for predicting overall survival and immune status in triple-negative breast cancer. Liu J; Ling Y; Su N; Li Y; Tian S; Hou B; Luo S; Zhao L; Shi M Transl Cancer Res; 2022 Jan; 11(1):181-192. PubMed ID: 35261895 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]